Payment overview · 2025
General Payments
$16,682.70
40 reported records · 7 companies
Healthcare provider profile · identity verified
Ashar Luqman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · SIOUX CITY, IA · NPI 1275742090
Verified facts
What the public records show
CMS Open Payments records show Ashar Luqman, M.D. received $16,682.70 in general payments during 2025 across 40 reported records.
Travere Therapeutics, Inc. accounted for 74.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Velphoro.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 571 claims for Jardiance by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Velphoro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 571 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12,379.88 | 74.2% | 19 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,889.46 | 17.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,110.00 | 6.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $153.14 | 0.9% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $97.79 | 0.6% | 1 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $33.22 | 0.2% | 2 | 2025 |
| NxStage Medical, Inc. | Unresolved — no canonical attribution shown | $19.21 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $9,600.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,875.00 | 3 |
| Travel and Lodging | $2,160.30 | 5 |
| Food and Beverage | $1,047.40 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $12,313.14 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $3,999.46 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $153.14 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $97.79 | 1 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| LIBERTY SELECT CYCLER Normalized: liberty select cycler |
Device | NxStage Medical, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | NxStage Medical, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 571 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 111 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
111 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
571 | 184 |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
571 | 184 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Allopurinol | Allopurinol | 4363 | 906 |
| Calcitriol | Calcitriol | 2750 | 637 |
| Furosemide | Furosemide | 2236 | 525 |
| Potassium Chloride | Potassium Chloride | 1594 | 397 |
| Spironolactone | Spironolactone | 1571 | 368 |
| Hydralazine Hcl | Hydralazine Hcl | 1534 | 330 |
| Farxiga | Dapagliflozin Propanediol | 1315 | 250 |
| Bumetanide | Bumetanide | 1302 | 326 |
| Losartan Potassium | Losartan Potassium | 904 | 248 |
| Metoprolol Tartrate | Metoprolol Tartrate | 774 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 719 | 180 |
| Cinacalcet Hcl | Cinacalcet Hcl | 687 | 167 |
| Metoprolol Succinate | Metoprolol Succinate | 647 | 165 |
| Jardiance | Empagliflozin | 571 | 184 |
| Clonidine Hcl | Clonidine Hcl | 501 | 136 |
| Carvedilol | Carvedilol | 403 | 114 |
| Lisinopril | Lisinopril | 385 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 95 |
| Acetazolamide | Acetazolamide | 276 | 68 |
| Prednisone | Prednisone | 241 | 70 |
| Metolazone | Metolazone | 233 | 72 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 214 | 59 |
| Januvia | Sitagliptin Phosphate | 211 | 35 |
| Gabapentin | Gabapentin | 202 | 47 |
| Oxybutynin Chloride | Oxybutynin Chloride | 180 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 67 |
| Cephalexin | Cephalexin | 176 | 72 |
| Glipizide | Glipizide | 176 | 51 |
| Midodrine Hcl | Midodrine Hcl | 161 | 73 |
| Omeprazole | Omeprazole | 160 | 38 |
| Irbesartan | Irbesartan | 159 | 41 |
| Potassium Citrate Er | Potassium Citrate | 159 | 44 |
| Cefdinir | Cefdinir | 151 | 119 |
| Glipizide Er | Glipizide | 148 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 47 |
| Torsemide | Torsemide | 142 | 32 |
| Nifedipine Er | Nifedipine | 131 | 34 |
| Kerendia | Finerenone | 111 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 110 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | 34 |
| Myrbetriq | Mirabegron | 100 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 27 |
| Metformin Hcl | Metformin Hcl | 94 | 35 |
| Ozempic | Semaglutide | 92 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 65 |
| Levofloxacin | Levofloxacin | 85 | 76 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 26 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 82 | 41 |
| Famotidine | Famotidine | 74 | 34 |
| Lokelma | Sodium Zirconium Cyclosilicate | 73 | 26 |
| Dapagliflozin | Dapagliflozin Propanediol | 72 | 23 |
| Sevelamer Carbonate | Sevelamer Carbonate | 72 | 26 |
| Lactulose | Lactulose | 69 | 23 |
| Febuxostat | Febuxostat | 67 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 17 |
| Benazepril Hcl | Benazepril Hcl | 62 | 13 |
| Montelukast Sodium | Montelukast Sodium | 59 | 13 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 20 |
| Eliquis | Apixaban | 58 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Calcium Acetate | Calcium Acetate | 51 | 18 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 50 | 26 |
| Chlorthalidone | Chlorthalidone | 49 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 33 |
| Fluconazole | Fluconazole | 48 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 18 |
| Finasteride | Finasteride | 46 | 16 |
| Glimepiride | Glimepiride | 45 | 12 |
| Novolog Flexpen | Insulin Aspart | 45 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 22 |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 33 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 14 |
| Megestrol Acetate | Megestrol Acetate | 31 | 12 |
| Veltassa | Patiromer Calcium Sorbitex | 31 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Tramadol Hcl | Tramadol Hcl | 30 | 26 |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Constulose | Lactulose | 27 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Renvela | Sevelamer Carbonate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Pulmicort Flexhaler | Budesonide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Atenolol | Atenolol | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 13 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,682.70 · 40 records | Travere Therapeutics, Inc. | Filspari, JARDIANCE, Kerendia, LIBERTY SELECT CYCLER, NXSTAGE SYSTEM ONE, PURIFIED CORTROPHIN GEL, VELPHORO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error